{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:19:46Z","timestamp":1791397186289,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Data on treatments for male breast cancer patients are limited owing to rarity and underrepresentation in clinical trials. The real-world POLARIS study gathers data on palbociclib use for the treatment of hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative (HR+\/HER2\u2013) advanced breast cancer (ABC) in female and male patients. This sub-analysis describes real-world palbociclib treatment patterns, clinical outcomes, and quality of life (QoL) in male patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>POLARIS is a prospective, noninterventional, multicenter, real-world study of patients with HR+\/HER2\u2013 ABC receiving palbociclib. Assessments included medical record reviews, patient QoL questionnaires (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire\u2013Core 30), site characteristics questionnaires, and physician treatment selection surveys. Variables included demographics, disease history, global health status\/QoL, clinical assessments and adverse events. Analyses were descriptive in nature. For clinical outcomes, real-world tumor responses and progression were determined by physician assessment in routine clinical practice. Real-world progression-free survival (rwPFS) was described using the Kaplan\u2013Meier method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At data cutoff, 15 male patients were enrolled (median age, 66 years). Nine patients received palbociclib as a first-line treatment and 6 as a second-line or later treatment. Patients received a median of 20 cycles of palbociclib. Neutropenia was experienced by 2 patients and grade\u2009\u2265\u20093 adverse events were reported in 11 patients. Global health status\/QoL scores remained generally consistent during the study. One patient (6.7%) achieved a complete tumor response, 4 (26.7%) a partial response, and 8 (53.3%) stable disease. Median rwPFS was 19.8 months (95% CI, 7.4\u201338.0). Median follow-up duration was 24.7 months (95% CI, 20.0\u201335.7).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This real-world analysis showed that palbociclib was well tolerated and provides preliminary data on treatment patterns and outcomes with palbociclib in male patients with HR+\/HER2\u2013 ABC, helping inform the use of palbociclib in this patient subgroup.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial identifier<\/jats:title>\n                <jats:p>NCT03280303.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-023-07145-1","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T20:01:43Z","timestamp":1698696103000},"page":"463-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Outcomes of male patients with HR+\/HER2\u2013 advanced breast cancer receiving palbociclib in the real-world POLARIS study"],"prefix":"10.1007","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7951-6645","authenticated-orcid":false,"given":"Joanne L.","family":"Blum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"DiCristo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan S.","family":"Karuturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oubre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Lakhanpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Z.","family":"Montelongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"7145_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"7145_CR2","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jamaoncol.2019.2803","volume":"5","author":"F Wang","year":"2019","unstructured":"Wang F, Shu X, Meszoely I, Pal T, Mayer IA, Yu Z, Zheng W, Bailey CE, Shu XO (2019) Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncol 5:1589\u20131596. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2803","journal-title":"JAMA Oncol"},{"key":"7145_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clbc.2017.03.005","volume":"17","author":"X Li","year":"2017","unstructured":"Li X, Yang J, Krishnamurti U, Huo L, Ward KC, O\u2019Regan R, Peng L (2017) Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin Breast Cancer 17:356\u2013366. https:\/\/doi.org\/10.1016\/j.clbc.2017.03.005","journal-title":"Clin Breast Cancer"},{"key":"7145_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69:438\u2013451. https:\/\/doi.org\/10.3322\/caac.21583","journal-title":"CA Cancer J Clin"},{"key":"7145_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10549-021-06182-y","volume":"188","author":"J Leone","year":"2021","unstructured":"Leone J, Freedman RA, Lin NU, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Leone JP (2021) Tumor subtypes and survival in male breast cancer. Breast Cancer Res Treat 188:695\u2013702. https:\/\/doi.org\/10.1007\/s10549-021-06182-y","journal-title":"Breast Cancer Res Treat"},{"key":"7145_CR6","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1056\/NEJMra1707939","volume":"378","author":"SH Giordano","year":"2018","unstructured":"Giordano SH (2018) Breast cancer in men. N Engl J Med 378:2311\u20132320. https:\/\/doi.org\/10.1056\/NEJMra1707939","journal-title":"N Engl J Med"},{"key":"7145_CR7","unstructured":"(2015) IBRANCE\u00ae (palbociclib). Full Prescribing Information. Pfizer Labs, a Division of Pfizer Inc, New York, NY"},{"key":"7145_CR8","unstructured":"(2017) VERZENIO\u00ae (abemaciclib). Full Prescribing Information. Eli Lilly and Company, Indianapolis, IN"},{"key":"7145_CR9","unstructured":"(2017) KISQALI\u00ae (ribociclib). Full Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ"},{"key":"7145_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","volume":"21","author":"JJ Gao","year":"2020","unstructured":"Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM (2020) CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 21:250\u2013260. https:\/\/doi.org\/10.1016\/S1470-2045(19)30804-6","journal-title":"Lancet Oncol"},{"key":"7145_CR11","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465\u20132472. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909","journal-title":"J Clin Oncol"},{"key":"7145_CR12","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-19-2580","volume":"26","author":"S Wedam","year":"2020","unstructured":"Wedam S, Fashoyin-Aje L, Bloomquist E, Tang S, Sridhara R, Goldberg KB, Theoret MR, Amiri-Kordestani L, Pazdur R, Beaver JA (2020) FDA approval summary: palbociclib for male patients with metastatic breast cancer. Clin Cancer Res 26:1208\u20131212. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2580","journal-title":"Clin Cancer Res"},{"key":"7145_CR13","doi-asserted-by":"publisher","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortes J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O\u2019Shaughnessy J, Rastogi P, on behalf of the monarchE Committee Members and Investigators, (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38:3987\u20133998. https:\/\/doi.org\/10.1200\/JCO.20.02514","DOI":"10.1200\/JCO.20.02514"},{"key":"7145_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-022-06543-1","volume":"193","author":"M Campone","year":"2022","unstructured":"Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, Palacova M, Chatterjee S, Menon-Singh L, Wu J, Martin M (2022) Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial. Breast Cancer Res Treat 193:95\u2013103. https:\/\/doi.org\/10.1007\/s10549-022-06543-1","journal-title":"Breast Cancer Res Treat"},{"key":"7145_CR15","unstructured":"Eli Lilly and Company (2021) News release: FDA approves Verzenio\u00ae (abemaciclib) as the first and only CDK4\/6 inhibitor for certain people with HR+ HER2- high risk early breast cancer. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-verzenior-abemaciclib-first-and-only-cdk46. Accessed 7 April 2022"},{"key":"7145_CR16","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/JCO.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS (2021) Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol 39:3959\u20133977. https:\/\/doi.org\/10.1200\/JCO.21.01392","journal-title":"J Clin Oncol"},{"key":"7145_CR17","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2217\/fon-2020-0573","volume":"16","author":"D Tripathy","year":"2020","unstructured":"Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y (2020) POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol 16:2475\u20132485. https:\/\/doi.org\/10.2217\/fon-2020-0573","journal-title":"Future Oncol"},{"key":"#cr-split#-7145_CR18.1","doi-asserted-by":"crossref","unstructured":"Blum JL, DiCristo C, Gordon D, Karuturi MS, Oubre D, Jepsen E, Cuevas J, Lakhanpal S, Zhang Z, Drucker M, Wang Y, Tripathy D (2021) Palbociclib (PAL) in male patients (pts) with hormone receptor-positive\/human epidermal growth factor receptor 2-negative (HR+\/HER2-) advanced breast cancer (ABC): pt characteristics and treatment","DOI":"10.1016\/j.annonc.2021.03.120"},{"key":"#cr-split#-7145_CR18.2","unstructured":"(Tx) patterns from the POLARIS study. Paper presented at European Society for Medical Oncology Breast Cancer (ESMO BC) Congress, Virtual, 5-8 May 2021"},{"key":"7145_CR19","unstructured":"Blum JL, DiCristo C, Gordon D, Karuturi MS, Oubre D, Jepsen E, Cuevas J, Lakhanpal S, Zhang Z, Drucker M, Wang Y, Tripathy D (2021) Male patients with HR+\/HER2\u2013 advanced breast cancer receiving palbociclib in a real-world setting: patient characteristics, treatment patterns, and outcomes in the POLARIS study. Paper presented at San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, 7\u201310 December 2021"},{"key":"7145_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"7145_CR21","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) EORTC QLQ-C30 scoring manual. European Organisation for Research and Treatment of Cancer, Brussels"},{"key":"7145_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/14656566.2017.1351947","volume":"18","author":"N Li","year":"2017","unstructured":"Li N, Du EX, Chu L, Peeples M, Xie J, Barghout V, Tang DH (2017) Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+\/HER2- metastatic breast cancer. Expert Opin Pharmacother 18:1167\u20131178. https:\/\/doi.org\/10.1080\/14656566.2017.1351947","journal-title":"Expert Opin Pharmacother"},{"key":"7145_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11523-021-00826-1","volume":"16","author":"A Brufsky","year":"2021","unstructured":"Brufsky A, Liu X, Li B, McRoy L, Layman RM (2021) Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol 16:601\u2013611. https:\/\/doi.org\/10.1007\/s11523-021-00826-1","journal-title":"Target Oncol"},{"key":"7145_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-021-01409-8","volume":"23","author":"A DeMichele","year":"2021","unstructured":"DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS (2021) Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+\/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res 23:37. https:\/\/doi.org\/10.1186\/s13058-021-01409-8","journal-title":"Breast Cancer Res"},{"key":"7145_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-018-0958-2","volume":"20","author":"JK Kish","year":"2018","unstructured":"Kish JK, Ward MA, Garofalo D, Ahmed HV, McRoy L, Laney J, Zanotti G, Braverman J, Yu H, Feinberg BA (2018) Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced\/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res 20:37. https:\/\/doi.org\/10.1186\/s13058-018-0958-2","journal-title":"Breast Cancer Res"},{"key":"7145_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2018.10.009","volume":"43","author":"G Taylor-Stokes","year":"2019","unstructured":"Taylor-Stokes G, Mitra D, Waller J, Gibson K, Milligan G, Iyer S (2019) Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+\/HER2-negative advanced\/metastatic breast cancer in real-world settings in the US: results from the IRIS study. Breast 43:22\u201327. https:\/\/doi.org\/10.1016\/j.breast.2018.10.009","journal-title":"Breast"},{"key":"7145_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-019-05176-1","volume":"176","author":"L Varella","year":"2019","unstructured":"Varella L, Eziokwu AS, Jia X, Kruse M, Moore HCF, Budd GT, Abraham J, Montero AJ (2019) Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat 176:429\u2013434. https:\/\/doi.org\/10.1007\/s10549-019-05176-1","journal-title":"Breast Cancer Res Treat"},{"key":"7145_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","volume":"29","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O\u2019Shaughnessy J (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29:1541\u20131547. https:\/\/doi.org\/10.1093\/annonc\/mdy155","journal-title":"Ann Oncol"},{"key":"7145_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425\u2013439. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0","journal-title":"Lancet Oncol"},{"key":"7145_CR30","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"7145_CR31","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:2875\u20132884. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585","journal-title":"J Clin Oncol"},{"key":"7145_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"key":"7145_CR33","unstructured":"Rocque GB, Blum JL, Montero A, Nakhoul I, Kurian S, Frank RC, Telivala B, Ajmera M, Coblentz D, Cappelleri JC, Wang Y, Tripathy D (2019) Quality of life in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world practice settings. In: 2019 San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX"},{"key":"7145_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M, PALOMA 3 Study Group (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209\u2013219. https:\/\/doi.org\/10.1056\/NEJMoa1505270","journal-title":"N Engl J Med"},{"key":"7145_CR35","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","volume":"27","author":"N Harbeck","year":"2016","unstructured":"Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, Andre F, Loi S, Verma S, Iwata H, Bhattacharyya H, Puyana Theall K, Bartlett CH, Loibl S (2016) Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol 27:1047\u20131054. https:\/\/doi.org\/10.1093\/annonc\/mdw139","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"7145_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2019.37.15_suppl.1055","volume":"37","author":"CH Bartlett","year":"2019","unstructured":"Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S, Decembrino J, Snow T, Carson KR, Rockland JM, Kraus RL, Wilner KD, Oharu N, Schnell P, Lu D, Tursi J (2019) Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET). J Clin Oncol 37(15 suppl):1055. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.1055","journal-title":"J Clin Oncol"},{"key":"7145_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41523-022-00479-x","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, Finn RS, DeMichele A (2022) Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+\/HER2- metastatic breast cancer. NPJ Breast Cancer 8:114. https:\/\/doi.org\/10.1038\/s41523-022-00479-x","journal-title":"NPJ Breast Cancer"},{"key":"7145_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6:116\u2013124. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782","journal-title":"JAMA Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07145-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T11:20:33Z","timestamp":1706008833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07145-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["7145"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07145-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"24 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Joanne L. Blum has received consulting fees from Puma Biotechnology, Athenex Inc, OncLive, Biotheranostics Inc, AstraZeneca, Immunomedics Inc, Research to Practice, Sanofi, Pfizer Inc and Tempus and has participated in Speaker\u2019s Bureaus for Pfizer Inc and Tempus. David Gordon, David Oubre, Juan Cuevas, and Shailendra Lakhanpal have no potential conflicts of interest to disclose. Meghan S. Karuturi has received consulting fees from Pfizer Inc. Erin Jepsen is an employee of Novant Health Cancer Institute. Caroline DiCristo, Zhe Zhang, Joseph Cappelleri, and Yao Wang are employees of Pfizer Inc and may hold stock or stock options. Debu Tripathy has received consulting fees from AstraZeneca, GlaxoSmithKline, OncoPep, AMBRX, Menarini-Stemline, Personalis, Puma Biotechnology, Roche and Sermonix and has performed contracted research for Pfizer Inc and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The study was conducted in accordance with legal and regulatory requirements. Prospective approvals of the study protocol and related documents were obtained from institutional review boards\/independent ethics committees for each site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}